Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19841979 | 0.91 | MEN1 (0.49) | MEN1KMT2APOLBNPSR1ALDH1A1 | |
| SCHEMBL21100502 | 0.85 | ALDH1A1 (0.43) | MEN1KMT2APOLBNPSR1ALDH1A1 | |
| SCHEMBL21165288 | 0.85 | ALDH1A1 (0.43) | MEN1KMT2APOLBNPSR1ALDH1A1 | |
| SCHEMBL21100503 | 0.85 | ALDH1A1 (0.43) | MEN1KMT2APOLBNPSR1ALDH1A1 | |
| SCHEMBL21100504 | 0.85 | ALDH1A1 (0.43) | MEN1KMT2APOLBNPSR1ALDH1A1 | |
| SCHEMBL19841946 | 0.84 | MEN1 (0.49) | MEN1KMT2APOLBNPSR1ALDH1A1 | |
| SCHEMBL19841947 | 0.82 | MEN1 (0.54) | MEN1KMT2APOLBNPSR1ALDH1A1 | |
| SCHEMBL18084853 | 0.82 | MEN1 (0.63) | MEN1KMT2ANPSR1MAPTTMEM97 | |
| SCHEMBL1128242 | 0.80 | MEN1 (0.71) | MEN1KMT2APOLBNPSR1ALDH1A1 | |
| SCHEMBL19934909 | 0.77 | FUCA1 (0.55) | MEN1KMT2APOLBALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-9884831-B2 | Azocane and azonane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, SLC10A1 | MEN1 2049/4885KMT2A 2234/4885POLB 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.